
Volta Finance Limited : Director/PDMR Shareholding
Volta Finance Limited (VTA/VTAS)
Notification of transactions by directors, persons discharging managerial
responsibilities and persons closely associated with them
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES
*****
Guernsey, 1 November 2023
Pursuant to the announcements made on 5 April 2019 and 26 June 2020 relating to changes to the payment of directors fees, Volta Finance Limited (the “Company” or “Volta”) has purchased 4,549 ordinary shares of no par value in the Company (“Ordinary Shares”) at an average price of €5.09 per share.
Each director receives 30% of their Director’s fees for any year in the form of shares, which they are required to retain for a period of no less than one year from their respective date of issue.
The shares will be issued to the Directors, who for the purposes of Regulation (EU) No 596/2014 on Market Abuse ("MAR") are "persons discharging managerial responsibilities" (a "PDMR").
- Dagmar Kershaw, Chairman and a PDMR for the purposes of MAR, acquired 1,152 additional Ordinary Shares in the Company. Following the settlement of this transaction, Ms Kershaw will have an interest in 9,605 Ordinary Shares, representing 0.03% of the issued shares of the Company;
- Stephen Le Page, Director and a PDMR for the purposes of MAR, acquired 979 additional Ordinary Shares in the Company. Following the settlement of this transaction, Mr Le Page will have an interest in 47,970 Ordinary Shares, representing 0.13% of the issued shares of the Company;
- Graham Harrison, Director and a PDMR for the purposes of MAR, acquired 806 additional Ordinary Shares in the Company. Following the settlement of this transaction, Mr Harrison will have an interest in 29,994 Ordinary Shares, representing 0.08% of the issued shares of the Company;
- Yedau Ogoundele, Director and a PDMR for the purposes of MAR acquired 806 additional Ordinary Shares in the Company. Following the settlement of this transaction, Mrs Ogoundele will have an interest in 4,598 Ordinary Shares, representing 0.01% of the issued shares of the Company; and
- Joanne Peacegood, Director and a PDMR for the purposes of MAR acquired 806 additional Ordinary Shares in the Company. Following the settlement of this transaction, Mrs Peacegood will have an interest in 1,085 Ordinary Shares, representing 0.01% of the issued shares of the Company;
The notifications below, made in accordance with the requirements of MAR, provide further detail in relation to the above transactions:
| ||||||
a) Dagmar Kershaw CHAIRMAN & DIRECTOR | b) Stephen Le Page DIRECTOR | c) Graham Harrison DIRECTOR | d) Yedau Ogoundele DIRECTOR | e) Joanne Peacegood DIRECTOR | ||
| ||||||
a. Position/status | Director | |||||
b. Initial notification/Amendment | Initial notification | |||||
| ||||||
a. Name | Volta Finance Limited | |||||
b. LEI | 2138004N6QDNAZ2V3W80 | |||||
| ||||||
a. Description of financial instrument, type of instrument | Ordinary Shares | |||||
b. Identification code | GG00B1GHHH78 | |||||
c. Nature of the transaction | Purchase and allocation of Ordinary Shares relation to the part-payment of Directors' fees for the quarter ended 31 July 2023 | |||||
d. Price(s) | €5.09 per share | |||||
e. Volume(s) | Total: 4,549 | |||||
f. Date of transaction | 1 November 2023 | |||||
g. Place of transaction | On-market – London | |||||
| ||||||
a) Dagmar Kershaw Chairman and Director | b) Steve Le Page Director | c) Graham Harrison Director | d) Yedau Ogoundele Director | e) Joanne Peacegood Director | ||
Aggr. Volume: 1,152 Price: €5.09 per share | Aggr. Volume: 979 Price: €5.09 per share | Aggr. Volume: 806 Price: €5.09 per share | Aggr. Volume: 806 Price: €5.09 per share | Aggr. Volume: 806 Price: €5.09 per share |
CONTACTS
For the Investment Manager
AXA Investment Managers Paris
Serge Demay
serge.demay@axa-im.com
+33 (0) 1 44 45 84 47
Company Secretary and Administrator
BNP Paribas S.A, Guernsey Branch
guernsey.bp2s.volta.cosec@bnpparibas.com
+44 (0) 1481 750 853
Corporate Broker
Cenkos Securities plc
Andrew Worne
Daniel Balabanoff
+44 (0) 20 7397 8900
*****
ABOUT VOLTA FINANCE LIMITED
Volta Finance Limited is incorporated in Guernsey under the Companies (Guernsey) Law, 2008 (as amended) and listed on Euronext Amsterdam and the London Stock Exchange's Main Market for listed securities. Volta’s home member state for the purposes of the EU Transparency Directive is the Netherlands. As such, Volta is subject to regulation and supervision by the AFM, being the regulator for financial markets in the Netherlands.
Volta’s Investment objectives are to preserve its capital across the credit cycle and to provide a stable stream of income to its Shareholders through dividends that it expects to distribute on a quarterly basis. The Company currently seeks to achieve its investment objectives by pursuing exposure predominantly to CLO’s and similar asset classes. A more diversified investment strategy across structured finance assets may be pursued opportunistically. The Company has appointed AXA Investment Managers Paris an investment management company with a division specialised in structured credit, for the investment management of all its assets.
*****
ABOUT AXA INVESTMENT MANAGERS
AXA Investment Managers (AXA IM) is a multi-expert asset management company within the AXA Group, a global leader in financial protection and wealth management. AXA IM is one of the largest European-based asset managers with 2,600 professionals and €824 billion in assets under management as of the end of December 2022.
*****
This press release is published by AXA Investment Managers Paris (“AXA IM”), in its capacity as alternative investment fund manager (within the meaning of Directive 2011/61/EU, the “AIFM Directive”) of Volta Finance Limited (the "Volta Finance") whose portfolio is managed by AXA IM.
This press release is for information only and does not constitute an invitation or inducement to acquire shares in Volta Finance. Its circulation may be prohibited in certain jurisdictions and no recipient may circulate copies of this document in breach of such limitations or restrictions. This document is not an offer for sale of the securities referred to herein in the United States or to persons who are “U.S. persons” for purposes of Regulation S under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or otherwise in circumstances where such offer would be restricted by applicable law. Such securities may not be sold in the United States absent registration or an exemption from registration from the Securities Act. Volta Finance does not intend to register any portion of the offer of such securities in the United States or to conduct a public offering of such securities in the United States.
*****
This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”) or (iii) high net worth companies, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). The securities referred to herein are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Past performance cannot be relied on as a guide to future performance.
*****
This press release contains statements that are, or may deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "anticipated", "expects", "intends", "is/are expected", "may", "will" or "should". They include the statements regarding the level of the dividend, the current market context and its impact on the long-term return of Volta Finance's investments. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Volta Finance's actual results, portfolio composition and performance may differ materially from the impression created by the forward-looking statements. AXA IM does not undertake any obligation to publicly update or revise forward-looking statements.
Any target information is based on certain assumptions as to future events which may not prove to be realised. Due to the uncertainty surrounding these future events, the targets are not intended to be and should not be regarded as profits or earnings or any other type of forecasts. There can be no assurance that any of these targets will be achieved. In addition, no assurance can be given that the investment objective will be achieved.
The figures provided that relate to past months or years and past performance cannot be relied on as a guide to future performance or construed as a reliable indicator as to future performance. Throughout this review, the citation of specific trades or strategies is intended to illustrate some of the investment methodologies and philosophies of Volta Finance, as implemented by AXA IM. The historical success or AXA IM’s belief in the future success, of any of these trades or strategies is not indicative of, and has no bearing on, future results.
The valuation of financial assets can vary significantly from the prices that the AXA IM could obtain if it sought to liquidate the positions on behalf of the Volta Finance due to market conditions and general economic environment. Such valuations do not constitute a fairness or similar opinion and should not be regarded as such.
Editor: AXA INVESTMENT MANAGERS PARIS, a company incorporated under the laws of France, having its registered office located at Tour Majunga, 6, Place de la Pyramide - 92800 Puteaux. AXA IMP is authorized by the Autorité des Marchés Financiers under registration number GP92008 as an alternative investment fund manager within the meaning of the AIFM Directive.
*****
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Managers’ transactions9.12.2023 18:12:40 CET | Press release
December 9, 2023 Announcement no. 21 Managers’ transactions COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 1. Details of the person discharging managerial responsibilities/person closely associated a) Name Singer Asefzadeh Family Holding Trust 2. Reason for the notification a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S b) Initial notification/amendment Initial notification 3. Details of the issuer a) Name BioPorto A/S b) LEI 5299004SWFL5JAN4W830 4. Details of the transaction(s) a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619 b) Nature o
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)9.12.2023 18:00:00 CET | Press release
Media Release COPENHAGEN, Denmark; December 9, 2023 Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcoritamab Results presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition include data from an optimized step-up dosing schedule for FL patients showing meaningful reduction in risk and severity of cytokine release syndrome (CRS) Follicular lymphoma is the second most common form of non-Hodgkin’s lymphoma, is considered incurable and can be difficult to treat in the R/R setting Genmab A/S (Nasdaq: GMAB) and AbbVie (NYSE: ABBV) todayannounced new data from the ongoing phase 1/2 EPCORE™ NHL-1 clinical trial investigating epcoritamab (DuoBody® CD3xCD20), a T-cell engaging bispecific antibody administered subcutaneously, demo
Galapagos presents new encouraging data at ASH 2023 from ongoing CD19 CAR-T studies with GLPG5201 and GLPG51019.12.2023 18:00:00 CET | Press release
Additional safety and efficacy data further support potential of innovative, decentralized approach to CAR-T manufacturing and transformational impact on patients with severe hematologic cancersTwo poster presentations include recent data updates and additional data not included in the ASH abstracts Galapagos to host a Key Opinion Leader (KOL) event with live webcast on Sunday, 10 December 2023 at 11:00 am PT/20:00 CET Mechelen, Belgium; 9 December 2023, 18:00 CET; Galapagos NV (Euronext & NASDAQ: GLPG) topresent additional encouraging clinical data from the ongoing Phase 1/2 CD19 CAR-T studies, EUPLAGIA-1 with GLPG5201 and ATALANTA-1 with GLPG5101, in patients with relapsed/refractory chronic lymphocytic leukemia (rrCLL), with or without Richter transformation, and non-Hodgkin lymphoma (rrNHL), during two poster sessions at the 65th American Society of Hematology (ASH) Annual Meeting taking place in San Diego, from 9-12 December. “We are very pleased to share promising new data from o
New data reinforce the benefit of early preventative treatment with Roche’s Hemlibra for babies with severe haemophilia A9.12.2023 17:30:00 CET | Press release
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth 1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma 1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed 1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with haemophilia A Basel, 09 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the primary analysis of the Phase III HAVEN 7 study reinforced the efficacy and safety of Hemlibra® (emicizumab) in previously untreated or minimally treated infants with severe haemophilia A without factor VIII inhibitors. Results showed that Hemlibra achieved meaningful
Bulletin from Annual General Meeting in SkiStar AB9.12.2023 16:00:00 CET | Press release
At SkiStar AB (publ)’s annual general meeting, held in Sälen on 9 December 2023, the following decisions were made. A dividend of SEK 2.60 per share was adopted. Record day 12 December 2023.Lena Apler, Fredrik Paulsson, Gunilla Rudebjer, Anders Sundström, Anders Svensson and Vegard Søraunet were re-elected to the board and Carina Åkerström was elected as new board member.Anders Sundström was re-elected chairman of the board.Board fees, including committee fees, were raised to a total of SEK 2,890,000 (2022: SEK 2,810,000). The fees shall be distributed as follows: SEK 670,000 (650,000) to the chairman of the board and SEK 310,000 (300,000) each to the other non-executive directors. Audit committee members will receive total fees of SEK 240,000 (unchanged), distributed as follows: SEK 120,000 to the committee chairman and SEK 60,000 to each of the other two members. Remuneration committee members will receive total fees of SEK 120,000 (unchanged), distributed as follows: SEK 60,000 to t